Key result
A 23-year-old male developed probable clozapine-induced parenchymal lung disease and perimyocarditis one week after starting treatment for schizophrenia.
Why the study?
Does clozapine cause concurrent perimyocarditis and parenchymal lung disease in patients with schizophrenia?
Case Report (n=1)
No
Does clozapine cause concurrent perimyocarditis and parenchymal lung disease in patients with schizophrenia?
Clozapine can rarely cause concurrent perimyocarditis and parenchymal lung disease, which should be considered as a diagnosis of exclusion in patients presenting with respiratory distress and heart failure after starting the drug.
Answers are grounded in this paper and cite their sources.
May support clozapine as rare cause of concurrent perimyocarditis and lung disease; hypothesis-generating and should not yet change practice.
BACKGROUND: Clozapine is the archetypical atypical antipsychotic, its primary indication being treatment resistant schizophrenia. Severe side effects caused by clozapine, including leukopenia, agranulocytosis, and myocarditis, are well known. A rarely described side effect is concurrent perimyocarditis and parenchymal lung disease. CASE PRESENTATION: A previously physically healthy 23-year-old male Caucasian that suffered from schizophrenia presented with flu-like symptoms 1 week after starting clozapine treatment. Treatment with clozapine was discontinued. He developed respiratory distress. Investigations showed significant parenchymal infiltration in both of the lungs, pericardial fluid, and heart failure. He initially received treatment for suspected malignant neuroleptic syndrome and later for suspected infection, but these tentative diagnoses were not confirmed. The patient's condition gradually improved. In retrospect, clozapine-induced parenchymal lung disease and perimyocarditis were deemed the most probable causes. CONCLUSIONS: Concurrent perimyocarditis and parenchymal lung disease are rare side effects of clozapine. Clozapine-induced disease in general is considered an exclusion diagnosis. Lacking a verifiable diagnosis when suspecting a side effect of clozapine, clinicians might treat the most likely and serious condition presenting and consider discontinuing clozapine until the diagnostic uncertainty is reasonably resolved.
No takes yet. Share an insight, caveat, or question.
Bugge et al. (2016) conducted a case report in Schizophrenia (n=1). Clozapine was evaluated on Development of adverse effects (parenchymal lung disease and perimyocarditis). A 23-year-old male developed probable clozapine-induced parenchymal lung disease and perimyocarditis one week after starting treatment for schizophrenia.
Synapse has enriched 10 related papers. Consider them for comparative context: